Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 37 min ago
Peer-reviewedCC BYJPGN reports

Diffuse gallbladder epithelial proliferation after teduglutide exposure: A case report.

  • Christopher P Duggan1,2
  • Alexandra N Carey1,2
  • Megan McGivney1
  • Mark Puder1,3
  • Antonio R Perez-Atayde4
4 affiliations
  1. 1Center for Advanced Intestinal Rehabilitation Boston Children's Hospital Boston Massachusetts USA.
  2. 2Division of Gastroenterology, Hepatology and Nutrition Boston Children's Hospital Boston Massachusetts USA.
  3. 3Department of Surgery Boston Children's Hospital Boston Massachusetts USA.
  4. 4Department of Pathology Boston Children's Hospital Boston Massachusetts USA.
Read full textPDFDOICite

Abstract

Teduglutide, a glucagon-like peptide 2 analog that increases mucosal proliferation in the gastrointestinal tract, was approved by the U.S. Food and Drug Administration for use in children with intestinal failure in 2019 after trials of 12- and 24-week duration. We report the case of a young patient treated with teduglutide for 5 years who developed diffuse gallbladder epithelial proliferation despite persistently normal biochemical hepatobiliary markers and the absence of cholelithiasis. Long-term use of teduglutide may warrant additional monitoring.

Related

  1. SDF-1 promotes migration, proliferation, and epithelial-mesenchymal plasticity of hepatocellular carcinoma cells via CXCR4-mediated histone deacetylation
    Siyi Cai, Tianshen Xiao, Zhongfei Luo +3
    Journal of Radiation Research and Applied SciencesPeer-reviewedCC BYFull textOncologyDOAJ
  2. ADH5 K113 Lactylation is Associated with Enhanced Glycolysis and Bladder Epithelial Cell Proliferation in Cystitis Glandularis.
    Yueyang Gong, Yongbo Tang, Shuangyan Chen +2
    Journal of inflammation researchPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  3. Risk-Window Palbociclib Exposure Delays ErbB2-Driven Mammary Tumorigenesis and Suppresses Mammary Epithelial Cell Stemness
    Y. Liu, A. B. Parris, Z. Ma +3
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  4. Testosterone exposure shifts female baseline phenotypes toward a male-associated tear-nerve-epithelial state in mice
    Nadege Feret, Alicia Caballero Megido, Sarah Pernot +12
    Scientific ReportsPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossref
  5. Bouveret Syndrome Mimicking Gallbladder Malignancy: A Diagnostic Challenge in an 85-Year-Old Woman
    Dominik Megias, Beat Oertli, Peter Bauerfeind
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{duggan2026diffuse,
  title = {{Diffuse gallbladder epithelial proliferation after teduglutide exposure: A case report.}},
  author = {Christopher P Duggan and Alexandra N Carey and Megan McGivney and Mark Puder and Antonio R Perez-Atayde},
  journal = {JPGN reports},
  year = {2026},
  month = oct,
  doi = {10.1002/jpr3.70284},
  url = {https://europepmc.org/article/MED/42953361},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Diffuse gallbladder epithelial proliferation after teduglutide exposure: A case report.
AU  - Christopher P Duggan
AU  - Alexandra N Carey
AU  - Megan McGivney
AU  - Mark Puder
AU  - Antonio R Perez-Atayde
PY  - 2026
DA  - 2026/10/28
JO  - JPGN reports
DO  - 10.1002/jpr3.70284
UR  - https://europepmc.org/article/MED/42953361
AB  - Teduglutide, a glucagon-like peptide 2 analog that increases mucosal proliferation in the gastrointestinal tract, was approved by the U.S. Food and Drug Administration for use in children with intestinal failure in 2019 after trials of 12- and 24-week duration. We report the case of a young patient treated with teduglutide for 5 years who developed diffuse gallbladder epithelial proliferation despite persistently normal biochemical hepatobiliary markers and the absence of cholelithiasis. Long-term use of teduglutide may warrant additional monitoring.
SN  - 2691-171X
ER  -